Anterior Approach to Improve the Prognosis in HCC Patients Via Decreasing Dissemination of EpCAM+ Circulating Tumor Cells

Hao, Shenghua; Chen, Shaofei; Tu, Caixue; Huang, Taotao

doi:10.1007/s11605-017-3410-5

Cited by 18 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in prior studies of the relationship between CTCs in postoperative peripheral blood and tumor recurrence, CTCs were commonly collected within 4–5 weeks after surgery. 27 , 28 Accordingly, we collected peripheral blood from HCC patients within 5 weeks after surgery to analyze the relationships between various CTC phenotypes and early recurrence. Our results further confirmed that postoperative mesenchymal CTCs were positively correlated with HCC recurrence and that the disease-free survival was significantly shortened in mesenchymal CTC-positive patients compared to mesenchymal CTC-negative patients.…”

Section: Discussionmentioning

confidence: 99%

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

Wang

Luo

Cheng

et al. 2018

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

BackgroundCirculating tumor cells (CTCs) have been actively studied for their functions in hepatocellular carcinoma (HCC) recurrence. However, the relationship between circulating tumor cells subtypes and hepatocellular carcinoma recurrence is still unclear.MethodsCTCs were collected from the peripheral blood of 62 postoperative HCC patients. The CTCs were isolated with a filtration-based method. Multiplex fluorescence in situ hybridization was used to characterize the CTCs based on mRNA expression levels of epithelial and mesenchymal markers.ResultsOf the 62 HCC patients, 26 were diagnosed with early recurrence (ER) and 36 did not experience recurrence. Comparison between the recurrence group and the non-recurrence group showed the total number of CTCs, mesenchymal CTCs, and mixed CTCs in the recurrence group was significantly higher than in the non-recurrence group. Receiver operator characteristic (ROC) curve analysis was performed to define the positive cutoff values as follows: total number of CTCs ≥ 4, mesenchymal CTCs ≥ 1, and mixed CTCs ≥ 3. Analysis showed that portal vein tumor thrombus (hazard ratio [HR] = 2.905, P = 0.023) and mesenchymal CTC positivity (HR = 3.453, P = 0.007) were independent risk factors for ER. The correlation between the presence of mesenchymal CTCs and time to recurrence was further examined, and the results showed significantly shortened postoperative disease-free survival in patients positive for mesenchymal CTCs (P < 0.001).ConclusionsHCC patients with positive peripheral mesenchymal CTCs have a more serious risk of ER, which could be a potential biomarker in HCC prognosis monitoring.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

Wang

Luo

Cheng

et al. 2018

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…Data suggested that surgery-induced manipulation of the liver is associated with a release of CTCs [94]. A comparison between anterior and conventional surgical approaches suggested that the latter was associated with a higher release of CTCs as well as poorer outcomes [89]. Toso et al described five steps during orthotopic liver transplant (OLT) in HCC patients to minimize CTC dissemination and thereby the risk of recurrence [104].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication

Labgaa

Villanueva

Dormond

et al. 2021

Cancers

View full text Add to dashboard Cite

Showing a steadily increasing cancer-related mortality, the epidemiological evolution of hepatocellular carcinoma (HCC) is concerning. Numerous strategies have attempted to prognosticate HCC but their performance is modest; this is partially due to the heterogeneous biology of this cancer. Current clinical guidelines endorse classifications and scores that use clinical variables, such as the Barcelona Clinic Liver Cancer (BCLC) classification. These algorithms are unlikely to fully recapitulate the genomic complexity of HCC. Integrating molecular readouts on a patient-basis, following a precision-medicine perspective, might be an option to refine prognostic systems. The limited access to HCC tissue samples is an important limitation to these approaches but it could be partially circumvented by using liquid biopsy. This concept consists of the molecular analysis of products derived from a solid tumor and released into biological fluids, mostly into the bloodstream. It offers an easy and minimally-invasive access to DNA, RNA, extracellular vesicles and cells that can be analyzed with next-generation sequencing (NGS) technologies. This review aims to investigate the potential contributions of liquid biopsy in HCC prognostication. The results identified prognostic values for each of the components of liquid biopsy, suggesting that this technology may help refine HCC prognostication.

show abstract

“…Cancer cell dissemination seems to be promoted by treatment, in particular surgical therapies. Liver manipulation is associated with a release of CTCs [ 215 ] and the anterior as compared to the conventional surgical approach is associated with a lower release of CTCs as well as better survival [ 216 ]. In liver transplantation for HCC, five steps to minimize CTCs dissemination and thereby reduce the risk of recurrence have been described [ 217 ].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Pelizzaro

Cardin

Penzo

et al. 2021

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Diagnostic, prognostic, and predictive biomarkers are urgently needed in order to improve patient survival. Indeed, the most widely used biomarkers, such as alpha-fetoprotein (AFP), have limited accuracy as both diagnostic and prognostic tests. Liver biopsy provides an insight on the biology of the tumor, but it is an invasive procedure, not routinely used, and not representative of the whole neoplasia due to the demonstrated intra-tumoral heterogeneity. In recent years, liquid biopsy, defined as the molecular analysis of cancer by-products, released by the tumor in the bloodstream, emerged as an appealing source of new biomarkers. Several studies focused on evaluating extracellular vesicles, circulating tumor cells, cell-free DNA and non-coding RNA as novel reliable biomarkers. In this review, we aimed to provide a comprehensive overview on the most relevant available evidence on novel circulating biomarkers for early diagnosis, prognostic stratification, and therapeutic monitoring. Liquid biopsy seems to be a very promising instrument and, in the near future, some of these new non-invasive tools will probably change the clinical management of HCC patients.

show abstract

Anterior Approach to Improve the Prognosis in HCC Patients Via Decreasing Dissemination of EpCAM+ Circulating Tumor Cells

Abstract: Like the liver-directed therapies, AA can reduce the dissemination of CTCs, especially in patients with large-size HCC (>5 cm) and successively improve the early prognosis.

Cited by 18 publications

References 26 publications

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Contact Info

Product

Resources

About